-Dendreon to Hold Conference Call on Tuesday, August 12, 2008 at 4:30 PM ET-

Thursday, August 7, 2008 General News J E 4
SEATTLE, Aug. 7 Dendreon Corporation(Nasdaq: DNDN) will hold its second quarter earnings call on Tuesday, August12, 2008. Company management will host the conference call at 1:30 p.m. PT(4:30 p.m. ET) to review second quarter financial results. Access to thediscussion may be obtained as follows:

A recorded rebroadcast will be available for interested parties unable toparticipate in the live conference call by dialing 1-888-203-1112 or+1-719-457-0820 for international callers; the conference ID number is5805154. The replay will be available from 7:30 pm ET on Tuesday, August 12until 11:59 pm ET on Thursday, August 14. In addition the webcast will bearchived for on-demand listening for 30 days at

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to targetcancer and transform lives through the discovery, development andcommercialization of novel therapeutics. The Company applies its expertise inantigen identification, engineering and cell processing to produce activecellular immunotherapy product candidates designed to stimulate an immuneresponse. Dendreon is also developing an orally-available small moleculecalled Trp-p8 that could be applicable to multiple types of cancer as well asbenign prostatic hyperplasia. The Company has its headquarters in Seattle,Washington and is traded on the Nasdaq Global Market under the symbol DNDN.For more information about the Company and its programs, visit 4:30 PM ET /1:30 PM PT Date: August 12, 2008 Dial-in: 1-877-545-1407 (domestic) or +1-719-325-4904 (international) Webcast: (homepage and investor relations section)

SOURCE Dendreon Corporation


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
IDM Pharma Reports Second Quarter Financial Result...
WaferGen to Present at the 28th Annual Canaccord A...